GET DAILY SIGNALSRelay Therapeutics (RLAY) Q3 2026 Earnings: Focus on Pipeline Progress
Key Takeaways
- Relay Therapeutics (RLAY) is expected to report third quarter 2026 results after the market closes on or around November 11, 2026, for the period ended September 30, 2026.
- Wall Street consensus points to a net loss of roughly $0.40 per share, with collaboration revenue of approximately $1.4 million — figures that reflect the company's pre-commercial, clinical-stage profile.
- Investor focus is expected to center on enrollment and execution updates for the Phase 3 ReDiscover-2 trial of zovegalisib (RLY-2608), the company's lead breast cancer candidate.
- The company held approximately $642 million in cash and investments as of March 31, 2026, a runway management has said should fund operations into 2029.
- Recent quarters have featured modest EPS (earnings per share) misses versus consensus, though operating expenses have declined as the company streamlined its research organization.
- For additional context on RLAY, dedicated pages cover major news, today's price action, price targets, and forecasts.
- Trending AI-driven strategies can also be reviewed to see how automated approaches are applied across the broader market.
Placing the Quarter in Context
Relay Therapeutics is a clinical-stage precision medicine company without approved products, so its quarterly reports matter more for pipeline updates and cash discipline than for top-line revenue. The central narrative continues to revolve around zovegalisib, the first pan-mutant selective PI3Kα inhibitor in clinical development and now in a Phase 3 trial for HR+/HER2- metastatic breast cancer. Revenue comes primarily from collaboration agreements, so investors scan each filing for trial milestones, spending patterns, and balance-sheet strength. Heading into the Q3 2026 release, the February 2026 FDA Breakthrough Therapy designation for zovegalisib and a track record of narrower-than-expected losses have shaped the backdrop. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What the Street Is Modeling
Consensus estimates for the third quarter of 2026 call for a net loss of about $0.40 per share and revenue near $1.4 million. That continues a pattern of relatively stable per-share losses: $0.41 in Q2 2026, $0.41 in Q1 2026, and $0.32 in Q4 2025. Revenue remains modest and uneven, driven by milestone payments from the Elevar Therapeutics license rather than product sales. Recent results have shown slight bottom-line misses — Q2 came in at $0.41 versus a $0.40 estimate and Q1 at $0.41 versus $0.36 — although Q4 2025 exceeded expectations. Analysts will therefore pay closer attention to R&D spending trends and any commentary on the ReDiscover-2 timeline than to the headline loss figure itself.
Investor Sentiment Ahead of the Print
Sentiment into the report is cautiously constructive yet data-dependent. The Breakthrough Therapy designation strengthened confidence in the lead asset, while the narrowing quarterly losses have supported the story of disciplined cost control. Shares remain highly sensitive to clinical updates rather than financial beats or misses. Potential risks include slower-than-expected enrollment in the Phase 3 ReDiscover-2 study, possible dilution via the at-the-market equity program, and ongoing pressure on pre-revenue biotech names amid shifting interest-rate and funding conditions. A muted reaction to the financials alone is likely unless management provides meaningful color on trial timelines or new data.
Key Items to Monitor Going Forward
The primary catalyst remains progress in the ReDiscover-2 Phase 3 trial of zovegalisib in HR+/HER2- metastatic breast cancer. Comments on enrollment pace, expected data readout timing, and regulatory plans will be closely watched. A triplet combination study with Pfizer’s atirmociclib is also advancing and could broaden the drug’s commercial potential. Beyond the lead program, the ReInspire Phase 1/2 trial in PI3Kα-driven vascular malformations offers an avenue into genetic-disease indications. Cost discipline will stay in focus as R&D and G&A expenses have trended lower following organizational streamlining. With roughly $642 million in cash and investments as of March 31, 2026, and a stated runway into 2029, the company looks funded through upcoming milestones, though any acceleration in late-stage spending could alter that outlook. Liquidity disclosures and share-count trends therefore merit attention.
Using Tickeron’s AI Screener in Biotech Research
In my own workflow I often turn to Tickeron’s AI Screener to quickly filter clinical-stage names by technical signals, fundamentals, and sector momentum. It surfaces comparable setups across the biotech universe in one view and helps me cross-check patterns without hours of manual work. For investors following names like RLAY, the tool adds efficiency when scanning for relative strength or breakout candidates.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
RLAY sees MACD Histogram just turned negative
RLAY saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 03, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 42 instances where the indicator turned negative. In 38 of the 42 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RLAY as a result. In 76 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
RLAY moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for RLAY crossed bearishly below the 50-day moving average on November 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RLAY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
RLAY broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for RLAY entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +4.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where RLAY advanced for three days, in 237 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.186) is normal, around the industry mean (2.904). P/E Ratio (-10.897) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (333.333) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. RLAY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 41 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RLAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage precision medicines company, which focuses on using innovative experimental and computational approaches on protein motion for making medicines against intractable precision medicine targets
Industry Biotechnology
Advertisement